Please login to the form below

Not currently logged in
Email:
Password:

olaparib

This page shows the latest olaparib news and features for those working in and with pharma, biotech and healthcare.

AZ, Merck’s Lynparza scores market-expanding clinical success

AZ, Merck’s Lynparza scores market-expanding clinical success

Positive phase 3 findings in ovarian cancer. Adding AstraZeneca and Merck’s Lynparza (olaparib) to Roche’s Avastin (bevacizumab) has improved outcomes in advanced ovarian cancer patients in a phase

Latest news

More from news
Approximately 11 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    olaparib) plus biologic PD-L1 immunotherapy Imfinzi (durvalumab). ... KUDOS had discovered olaparib, the first-in- class PARP inhibitor, which Galbraith’s team developed and brought to market as Lynparza.

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    and was the pharma company with the most approvals from the US FDA with four last year, including the diabetes drug Farxiga (dapagliflozin) and Lynparza (olaparib) for ovarian cancer.

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    But now hopes are high for two late-stage drugs: olaparib and selumetinib.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics